|
1
|
CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling.
|
Nature
|
2006
|
2.35
|
|
2
|
Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
|
Clin Cancer Res
|
2009
|
1.23
|
|
3
|
SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells.
|
Cancer Res
|
2008
|
1.09
|
|
4
|
Dynamics of Golgi matrix proteins after the blockage of ER to Golgi transport.
|
J Biochem
|
2004
|
1.05
|
|
5
|
Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.
|
Clin Cancer Res
|
2009
|
1.03
|
|
6
|
An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.
|
Anticancer Agents Med Chem
|
2009
|
0.96
|
|
7
|
TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo.
|
PLoS One
|
2013
|
0.87
|
|
8
|
Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay.
|
Oncology
|
2007
|
0.84
|
|
9
|
Expression Analysis of p16, c-Myc, and mSin3A in Non-small Cell Lung Cancer by Computer Aided Scoring and Analysis (CASA).
|
Clin Lab
|
2015
|
0.80
|
|
10
|
Relationship of Amplification and Expression of the C-MYC Gene with Survival among Gastric Cancer Patients.
|
Asian Pac J Cancer Prev
|
2015
|
0.77
|
|
11
|
Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
|
Clin Lab
|
2015
|
0.77
|